CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Phase 2
Toronto, Ontario, Canada and 24 other locations
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Toronto, Canada and 44 other locations
the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...
Phase 3
Toronto, Ontario, Canada and 154 other locations
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...
Phase 2
Toronto, Ontario, Canada and 43 other locations
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...
Phase 2
Toronto, Canada and 55 other locations
antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...
Phase 2, Phase 3
Toronto, Ontario, Canada and 65 other locations
of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...
Phase 2
Toronto, Ontario, Canada and 65 other locations
not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...
Phase 3
Toronto, Ontario, Canada and 189 other locations
be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab o...
Phase 2
Toronto, Ontario, Canada and 32 other locations
and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...
Phase 3
Toronto, Ontario, Canada and 128 other locations
Clinical trials
Research sites
Resources
Legal